Does cannabis extract obtained from cannabis flowers with maximum allowed residual level of aflatoxins and ochratoxin A have an impact on human safety and health?
Posted on March 8, 2022 By LabLynx Journal articles
Contents
Tools
Actions
General
- What links here
- Related changes
- Upload file
- Special pages
- Permanent link
- Page information
- Cite this page
- Get shortened URL
- Download QR code
- Wikidata item
Print/export
- Download as PDF
- Printable version
In other projects
Chemical compound
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C19H21F2N3O |
Molar mass | 345.394 g·mol−1 |
3D model (JSmol) | |
| |
|
Tedalinab (GRC-10693) is a drug developed by Glenmark Pharmaceuticals for the treatment of osteoarthritis and neuropathic pain, which acts as a potent and selective cannabinoid CB2 receptor agonist. It has a very high selectivity of 4700x for CB2 over the related CB1 receptor, has good oral bioavailability and has shown promising safety results and effective analgesic and antiinflammatory actions in early clinical trials.[1] Many related compounds are known, most of which also show high CB2 selectivity.[2]
See also
References
- ^ Glenmark’s Molecule for Neuropathic Pain, Osteoarthritis - GRC 10693, Successfully Completes Phase I Trials. April 13, 2009.
- ^ Glenmark Pharmaceuticals. NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION, Filed June 1st, 2006. WO 2006/129178.
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|
by LabLynx